RANOLAZINE IN ISCHEMIC HEART DISEASE
Study results of a new anti-anginal drug (an inhibitor of sodium channels — ranolazine) are presented. Indications, contraindications, major clinical trials of the drug in patients with ischemic heart disease are considered.
Saved in:
Main Author: | V. P. Lupanov |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2015-12-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/423 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modern strategy, management and outcomes for stable ischemic heart disease patients
by: V. P. Lupanov
Published: (2016-02-01) -
THE INFLUENCE OF PSYCHOSOCIAL FACTORS ON THE DEVELOPMENT OF ISCHEMIC HEART DISEASE AND ACUTE CORONARY SYNDROME
by: K. G. Kozhokar, et al.
Published: (2016-06-01) -
HIGH SELECTIVE LONG-ACTING Β1-BLOCKER WITH A VASODILATING EFFECT NEBIVOLOL IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015-12-01) -
THE PROBLEM OF INTERCHANGEABILITY OF DRUG PRODUCTS. TRIMETAZIDINE IS AN EFFECTIVE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE
by: L. E. Chekuldaeva, et al.
Published: (2015-12-01) -
MYOCARDIAL REMODELING IN ISCHEMIC HEART DISEASE
by: A. N. Zakirova, et al.
Published: (2016-01-01)